ALK and neoplasm: Our previous research demonstrated that RNase1 can promote immune progression in hepatocellular carcinoma by activating ALK signaling pathway in macrophages, thereby reshaping the tumor immune microenvironment.31 However, whether RNase1 directly functions as a tumor-driving factor remains uncertain.